RO7198457, KEYTRUDA 25 mg/mL concentrate for solution for infusion clinical trials

A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of RO7198457 in Combination With Pembrolizumab Versus Pembrolizumab in Patients with Previously Untreated Advanced Melanoma

This study looks at a new drug, RO7198457, combined with an existing drug, Keytruda, for advanced melanoma. We want to see if this combination works better than Keytruda alone to slow down cancer growth and improve patients' lives, while also checking for any side effects.